Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 earnings results
Vertex Pharmaceuticals Incorporated (VRTX) reported Q3 2026 results on Nov 2, 2026, 4:05:46 PM ET: GAAP EPS $2.56; revenue $3.44B. Outlook: Full-year 2026 revenue guidance raised to $13.15 billion to $13.25 billion.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | $2.56 | — | — |
| Revenue | $3.44B | — | — |
Analyst estimate: the average forecast before the release. No EPS comparison is shown when the company's reported basis (GAAP or adjusted) differs from the forecast's or no forecast was available.
Source
Figures from the SEC 8-K filing, released Nov 2, 2026, 4:05:46 PM ET. Nexqual published them 48 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 11.8% from $3.08B; GAAP diluted EPS was $2.56 vs. $4.20 (−39.0%).
Stock reaction
The results came out after the market closed. VRTX is trading at $543.70 as of 10:17 AM ET on November 3, 2026, down 1.7% from its $553.15 close on November 2, 2026 before the results.
Questions and answers
Did Vertex Pharmaceuticals Incorporated beat earnings expectations?
Nexqual has no comparable analyst EPS estimate for this report (the forecast may be on a different basis than the reported GAAP or adjusted figure). Reported: GAAP EPS $2.56; revenue $3.44B.
What were Vertex Pharmaceuticals Incorporated's Q3 2026 earnings and revenue?
GAAP diluted EPS of $2.56 and revenue of $3.44B. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 11.8% from $3.08B; GAAP diluted EPS was $2.56 vs. $4.20 (−39.0%).
When did Vertex Pharmaceuticals Incorporated report Q3 2026 earnings?
Nov 2, 2026, 4:05:46 PM ET, in an SEC 8-K filing (Item 2.02).
How did VRTX stock react to the earnings?
The results came out after the market closed. VRTX is trading at $543.70 as of 10:17 AM ET on November 3, 2026, down 1.7% from its $553.15 close on November 2, 2026 before the results.
What did Vertex Pharmaceuticals Incorporated say about its outlook?
Full-year 2026 revenue guidance raised to $13.15 billion to $13.25 billion.
More on VRTX
VRTX stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 2, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 3, 2026 at 15:17 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 3, 2026 at 15:17 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt